Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Consensus Rating of "Moderate Buy" From Analysts
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Consensus Rating of "Moderate Buy" From Analysts
Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) have been assigned a consensus recommendation of "Hold" from the six research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $1.88.
Aeglea 生物治療學公司（NASDAQ：AGLE — 獲得評級）的股份已從六家涵蓋該股票的研究公司獲得「持有」的共識建議，MarketBeat.com 報告。三位投資分析師對該股票進行了持有建議進行了評級，兩名分析師向該公司分配了買入建議。去年對股票發行評級的經紀人中，平均 12 個月的價格目標為 1.88 美元。
Several equities analysts recently issued reports on the company. StockNews.com assumed coverage on Aeglea BioTherapeutics in a research note on Monday. They set a "hold" rating on the stock. Piper Sandler increased their price objective on Aeglea BioTherapeutics to $1.50 in a report on Tuesday, November 1st. Finally, Wells Fargo & Company upgraded Aeglea BioTherapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $1.50 to $2.00 in a report on Friday, October 28th.
幾位股票分析師最近發表了有關該公司的報告。Stocknews.com 在周一的研究筆記中承擔了艾格勒生物治療學的報導。他們設置了股票的「持有」評級。吹笛者桑德勒在 11 月 1 日（星期二）的一份報告中，將 Aeglea 生物治療學的價格目標提高到 1.50 美元。最後，富國銀行公司將 Aeglea 生物治療從「同等體重」評級為「超重」評級，並在 10 月 28 日（星期五）的報告中將該公司的價格目標從 $1.50 提高到 2.00 美元。
Aeglea BioTherapeutics Stock Performance
AEGLEA 生物治療股票表現
NASDAQ:AGLE opened at $0.48 on Tuesday. The firm's fifty day moving average is $0.54 and its two-hundred day moving average is $0.60. Aeglea BioTherapeutics has a one year low of $0.34 and a one year high of $4.54. The firm has a market cap of $29.65 million, a price-to-earnings ratio of -0.42 and a beta of 1.66.
納斯達克：阿格爾在周二開盤 $0.48。該公司的五十日移動平均線為 0.54 美元，其 200 日移動平均線為 0.60 美元。Aeglea 生物治療學的一年低點為 0.34 美元，一年高點為 4.54 美元。該公司的市值為 29.65 萬美元，價格與收益比為 -0.42，測試版為 1.66。
Institutional Inflows and Outflows
機構流入和流出
Several large investors have recently modified their holdings of AGLE. Bain Capital Life Sciences Investors LLC boosted its position in Aeglea BioTherapeutics by 87.8% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock valued at $2,701,000 after buying an additional 2,500,000 shares during the last quarter. Pictet Asset Management SA grew its position in Aeglea BioTherapeutics by 91.6% in the 2nd quarter. Pictet Asset Management SA now owns 4,890,502 shares of the biotechnology company's stock worth $2,470,000 after purchasing an additional 2,338,068 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Aeglea BioTherapeutics by 21.1% in the second quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock valued at $1,958,000 after acquiring an additional 676,718 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Aeglea BioTherapeutics by 283.5% in the second quarter. Renaissance Technologies LLC now owns 582,444 shares of the biotechnology company's stock valued at $294,000 after acquiring an additional 430,576 shares in the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in Aeglea BioTherapeutics by 14.8% during the first quarter. Rock Springs Capital Management LP now owns 1,811,425 shares of the biotechnology company's stock worth $4,166,000 after buying an additional 234,129 shares in the last quarter. 78.01% of the stock is currently owned by hedge funds and other institutional investors.
一些大型投資者最近修改了他們對 AGLE 的持有量。貝恩資本生命科學投資者有限責任公司在 Aeglea 生物治療學的地位在第二季度提高了 87.8％。貝恩資本生命科學投資者有限責任公司現在擁有 5,347,689 股價值 2701,000 美元的生物技術公司股票，價值在上一季度額外購買 2,500,000 股股票後。瑞士百達資產管理 SA 第二季度在艾格勒生物治療領域的地位增長了 91.6%。瑞士百達資產管理股份有限公司在上一季度額外購買 2,338,068 股股票後，擁有該生物科技公司股票價值 2,470,000 美元的 4,890,502 股。楠塔哈拉資本管理有限責任公司在第二季度將其 Aeglea 生物治療學股份的持有量提高了 21.1％。南大哈拉資本管理有限責任公司現在擁有該生物技術公司股票的 3,877,311 股價值 1,958,000 美元，在上個季度另外收購 676,718 股股票後，該公司股票價值為 1,958,000 美元。文藝復興技術有限責任公司在第二季度將 Aeglea 生物治療學股份的持有量提高了 283.5％。文藝復興技術有限責任公司現在擁有 582,444 股價值 294,000 美元的生物技術公司股票，價值在上個季度另外收購 430,576 股後。最後，羅克斯普林斯資本管理有限公司在第一季度將其在 Aeglea 生物治療學的持有量提高了 14.8％。羅克斯普林斯資本管理有限公司在上一季度額外購買 234,129 股股票後，現在擁有該生物技術公司股票的 1,811,425 股，價值 4,166,000 美元。78.01％ 的股票目前由對沖基金和其他機構投資者擁有。
About Aeglea BioTherapeutics
關於艾格列生物治療
(Get Rating)
(取得評分)
Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
Aeglea BioTheraptics, Inc 是一家臨床階段的生物技術公司，致力於開發下一代人類酵素療法，作為罕見和其他高負擔疾病的破壞性解決方案。其產品聚乙胺精氨酸酶正處於治療精氨酶 1 缺乏症的 3 期關鍵試驗中。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 獲取有關艾格勒生物療法研究報告的免費副本
- 為什麼黃金現在可以成為您的投資組合中閃閃發光的補充
- SoFi 技術打破收益，但要小心美聯儲決定
- 購買高露潔棕櫚樹的浸
- 馬倫汽車在招聘狂歡, 這可能意味著什麼?
- 數位互聯提出其收益指引
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Aeglea 生物治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Aeglea 生物治療及相關公司的最新新聞和分析師評級的簡要每日摘要。